Aspen Offers Commitments To Settle EU Price Gouging Claims
Three-Year Investigation Would Close If Company Suggestions Adopted
Executive Summary
After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.
You may also be interested in...
US, EU and UK Antitrust Enforcers Form Pharma Monitoring Taskforce
Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation.
EU Accepts Aspen Price Commitments
Commitments offered by Aspen Pharmacare last year to settle price-gouging allegations over six oncology drugs have been accepted by the European Commission.
Aspen Says Reshaping Has Been ‘Painful’ But Is Over Now
Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.